Lineage Cell Therapeutics
Company
Lineage Cell Therapeutics develops 7 assets, the furthest in phase 2 (OPC1 in spinal cord injury). Mostly cell therapy acting on stem cell maintenance.
- 7
- Assets
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
7Phase 2, Cell therapy, spinal cord injury
Retinal pigment epithelial cell therapy replaces or supports dysfunctional or absent cells.
Phase 2, Cell therapy, Stem cell maintenance, dry AMD, geographic atrophy
Stage not known, Cell therapy
4 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Deals6
- People12
- Similar companies6